Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3819MR)

This product GTTS-WQ3819MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3819MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4458MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ2200MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ9297MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ4163MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ14099MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ8573MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ6500MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ10175MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LC1004-002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW